<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367912</url>
  </required_header>
  <id_info>
    <org_study_id>ZTB</org_study_id>
    <nct_id>NCT01367912</nct_id>
  </id_info>
  <brief_title>Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle</brief_title>
  <official_title>Timing of Estrogen Support During the Luteal Phase of IVF / Intracytoplasmic Sperm Injection Cycle: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that adding estradiol (E2) to progesterone supplementation later in
      the luteal phase of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI)
      cycles, rather than earlier in the luteal phase, improves clinical pregnancy rates (PRs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies reported that elevated E2 may have a detrimental effect on endometrial
      receptivity and embryo. This conflict was the starting point of our study. The investigators
      thought that this luteal decrease in E2 level could be prevented by adding estradiol just
      before the receptivity window is open, instead of adding earlier in the luteal phase which
      could result in defective embryo implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>sixth gestational week.</time_frame>
    <description>Clinical pregnancies were detected with the confirmation of positive fetal cardiac activities by transvaginal sonography in the sixth gestational week.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Progesterone only group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone+Early Estradiol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone+Late estradiol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol tablet</intervention_name>
    <description>received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel</description>
    <arm_group_label>Progesterone+Early Estradiol group</arm_group_label>
    <other_name>estrofem 2 mg tablet, Novo Nordisk, Bagsvaerd, Denmark</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol tablet</intervention_name>
    <description>received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.</description>
    <arm_group_label>Progesterone+Late estradiol group</arm_group_label>
    <other_name>estrofem 2 mg tablet, Novo Nordisk, Bagsvaerd, Denmark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients on long GnRH agonist protocol with controlled ovarian hyperstimulation
             who were seen in our IVF clinic between February and November 2008, and who have E2
             levels on the day of hCG administration &gt;2500 pg/dl

        Exclusion Criteria:

          -  Presence of azoospermia requiring testicular sperm extraction procedure

          -  endometriosis greater than stage II

          -  unilateral oophorectomy, polycystic ovarian syndrome (PCOS)

          -  secondary infertility

          -  age greater than 40 yrs and a basal follicle stimulating hormone (FSH) level higher
             than 12 mIU/ml were exclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leyla Mollamahmutoğlu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zekai Tahir Burak Maternity and Teaching Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06220</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ubaldi F, Bourgain C, Tournaye H, Smitz J, Van Steirteghem A, Devroey P. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril. 1997 Mar;67(3):521-6.</citation>
    <PMID>9091341</PMID>
  </reference>
  <reference>
    <citation>Kolibianakis EM, Devroey P. The luteal phase after ovarian stimulation. Reprod Biomed Online. 2002;5 Suppl 1:26-35. Review.</citation>
    <PMID>12537779</PMID>
  </reference>
  <reference>
    <citation>Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003 Jul;14(5):236-42. Review.</citation>
    <PMID>12826330</PMID>
  </reference>
  <reference>
    <citation>Devreker F, Govaerts I, Bertrand E, Van den Bergh M, Gervy C, Englert Y. The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate. Fertil Steril. 1996 Jan;65(1):122-6.</citation>
    <PMID>8557126</PMID>
  </reference>
  <reference>
    <citation>Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev. 2004;(3):CD004830. Review. Update in: Cochrane Database Syst Rev. 2008;(3):CD004830.</citation>
    <PMID>15266541</PMID>
  </reference>
  <reference>
    <citation>Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002 Sep;17(9):2287-99. Review.</citation>
    <PMID>12202415</PMID>
  </reference>
  <reference>
    <citation>Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril. 2010 Feb;93(2):428-36. doi: 10.1016/j.fertnstert.2009.02.033. Epub 2009 Apr 1.</citation>
    <PMID>19342034</PMID>
  </reference>
  <reference>
    <citation>Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008 Dec;90(6):2116-25. doi: 10.1016/j.fertnstert.2007.10.053. Epub 2008 Jan 7. Review.</citation>
    <PMID>18178194</PMID>
  </reference>
  <reference>
    <citation>Kolibianakis EM, Venetis CA, Papanikolaou EG, Diedrich K, Tarlatzis BC, Griesinger G. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Hum Reprod. 2008 Jun;23(6):1346-54. doi: 10.1093/humrep/den115. Epub 2008 Apr 11. Review.</citation>
    <PMID>18408017</PMID>
  </reference>
  <reference>
    <citation>Buvat J, Marcolin G, Guittard C, Dehaene JL, Herbaut JC, Louvet AL. [Luteal support after administration of an LHRH analog for in vitro fertilization. Superiority of vaginal progesterone in comparison with oral progesterone]. Presse Med. 1990 Mar 24;19(11):527. French.</citation>
    <PMID>2138757</PMID>
  </reference>
  <reference>
    <citation>Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2000 Apr;73(4):761-6.</citation>
    <PMID>10731538</PMID>
  </reference>
  <reference>
    <citation>Bergh PA, Navot D. The impact of embryonic development and endometrial maturity on the timing of implantation. Fertil Steril. 1992 Sep;58(3):537-42.</citation>
    <PMID>1521649</PMID>
  </reference>
  <reference>
    <citation>Muasher S, Acosta AA, Garcia JE, Jones GS, Jones HW Jr. Luteal phase serum estradiol and progesterone in in vitro fertilization. Fertil Steril. 1984 Jun;41(6):838-43.</citation>
    <PMID>6427017</PMID>
  </reference>
  <reference>
    <citation>Yang JH, Chen HF, Lien YR, Chen SU, Ho HN, Yang YS. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate. J Reprod Med. 2001 May;46(5):434-8.</citation>
    <PMID>11396368</PMID>
  </reference>
  <reference>
    <citation>Valbuena D, Martin J, de Pablo JL, Remohí J, Pellicer A, Simón C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertil Steril. 2001 Nov;76(5):962-8.</citation>
    <PMID>11704118</PMID>
  </reference>
  <reference>
    <citation>Smitz J, Bourgain C, Van Waesberghe L, Camus M, Devroey P, Van Steirteghem AC. A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum Reprod. 1993 Jan;8(1):40-5.</citation>
    <PMID>8458924</PMID>
  </reference>
  <reference>
    <citation>Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2005 May;83(5):1372-6.</citation>
    <PMID>15866571</PMID>
  </reference>
  <reference>
    <citation>Lewin A, Benshushan A, Mezker E, Yanai N, Schenker JG, Goshen R. The role of estrogen support during the luteal phase of in vitro fertilization-embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertil Steril. 1994 Jul;62(1):121-5.</citation>
    <PMID>8005275</PMID>
  </reference>
  <reference>
    <citation>Tay PY, Lenton EA. Inhibition of progesterone secretion by oestradiol administered in the luteal phase of assisted conception cycles. Med J Malaysia. 2003 Jun;58(2):187-95.</citation>
    <PMID>14569738</PMID>
  </reference>
  <reference>
    <citation>Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988 Jul;3(5):585-90.</citation>
    <PMID>3139698</PMID>
  </reference>
  <reference>
    <citation>Younis JS, Ezra Y, Sherman Y, Simon A, Schenker JG, Laufer N. The effect of estradiol depletion during the luteal phase on endometrial development. Fertil Steril. 1994 Jul;62(1):103-7.</citation>
    <PMID>8005273</PMID>
  </reference>
  <reference>
    <citation>Vlahos NF, Lipari CW, Bankowski B, Lai TH, King JA, Shih IeM, Fragakis K, Zhao Y. Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization. J Clin Endocrinol Metab. 2006 Oct;91(10):4043-9. Epub 2006 Jul 25.</citation>
    <PMID>16868054</PMID>
  </reference>
  <reference>
    <citation>Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril. 2008 Mar;89(3):554-61. Epub 2007 Aug 2.</citation>
    <PMID>17678651</PMID>
  </reference>
  <reference>
    <citation>Gorkemli H, Ak D, Akyurek C, Aktan M, Duman S. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles. Gynecol Obstet Invest. 2004;58(3):140-4. Epub 2004 Jun 15.</citation>
    <PMID>15205566</PMID>
  </reference>
  <reference>
    <citation>Serna J, Cholquevilque JL, Cela V, Martínez-Salazar J, Requena A, Garcia-Velasco JA. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial. Fertil Steril. 2008 Dec;90(6):2190-5. doi: 10.1016/j.fertnstert.2007.10.021. Epub 2008 Jan 14.</citation>
    <PMID>18191847</PMID>
  </reference>
  <results_reference>
    <citation>Pouly JL, Piekrishvili R, Beaume-BrugonF, Schubert B, Janny L. Luteal phase supplementation with oestrogens doesn't improve the IVF pregnancy rate: a randomized study. Hum Reprod 2005; 20:O- 195.</citation>
  </results_reference>
  <results_reference>
    <citation>Tonguc E, Var T, Ozyer S, Citil A, Dogan M. Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. Eur J Obstet Gynecol Reprod Biol. 2011 Feb;154(2):172-6. doi: 10.1016/j.ejogrb.2010.10.003. Epub 2010 Nov 9.</citation>
    <PMID>21067858</PMID>
  </results_reference>
  <results_reference>
    <citation>Causio F, Leonetti T. Luteal phase support with estrogen and progesterone in in vitro fertilization cycles using GnRHa and FSH. Gior Ital Ostet Ginecol 1997; 19: 277-82.</citation>
  </results_reference>
  <results_reference>
    <citation>Rashidi BH, Asheghan H, Jafarabadi M, Tehrani NE. The role of estrogen supplementation during the luteal phase in in vitro fertilization-embryo transfer cycles: a comparative study between progesterone and estrogen plus progesterone support. Proceedings of the 18th World Congress on Fertility and sterility; 2004 May 23-28; Montreal, Canada. Internatioanal Congress Series; 2004.p.120-123.</citation>
  </results_reference>
  <results_reference>
    <citation>Elnashar AM, Aboul-Enein GI. Endometrial receptivity. Middle East Fertil Soc J 2004; 9 (1): 10-24).</citation>
  </results_reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Institutional review board</name_title>
    <organization>Zekai Tahir Burak Maternity and Teaching Hospital, Murat ÖZEL, M.D.</organization>
  </responsible_party>
  <keyword>Luteal phase support</keyword>
  <keyword>estradiol supplementation</keyword>
  <keyword>IVF/ICSI</keyword>
  <keyword>clinical pregnancy rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

